Page 1550 - Williams Hematology ( PDFDrive )

1524 Part XI: Malignant Lymphoid Diseases Chapter 91: Acute Lymphoblastic Leukemia 1525

195. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lym- 218. Campana D, Leung W: Clinical significance of minimal residual disease in patients with
phoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol
transplantation in first complete remission, and an autologous transplantation is less 162:147, 2013.
effective than conventional consolidation/maintenance chemotherapy in all patients: 219. Wassermann B, Pfeifer H, Stadler M, et al: Early molecular response to posttransplanta-
Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood tion imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic
111:1827, 2008. leukemia (PH+ALL). Blood 106:458, 2005.
196. Gupta V, Richards S, Rowe J, Acute Leukemia Stem Cell Transplantation Trialists’ Col- 220. Thomas DA, O’Brien S, Jorgensen JL, et al: Prognostic significance of CD20 expres-
laborative Group: Allogeneic, but not autologous, hematopoietic cell transplantation sion in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood
improves survival only among younger adults with acute lymphoblastic leukemia in 113:6330, 2009.
first remission: An individual patient data meta-analysis. Blood 121:339, 2013. 221. Jeha S, Behm F, Pei D, et al: Prognostic significance of CD20 expression in childhood
197. Mark DJ, Perez WS, He W, et al: Unrelated donor transplants in adults with Philadelphia- B-cell precursor acute lymphoblastic leukemia. Blood 108:3302, 2006.
negative acute lymphoblastic leukemia in first complete remission. Blood 112:426, 2008. 222. Thomas DA, O’Brien S, Faderl S, et al: Chemoimmunotherapy with a modified hyper-
198. Aricò M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Phil- CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-
adelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998, negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28:3880, 2010.
2000. 223. Advani AS: New immune strategies for the treatment of acute lymphoblastic leukemia:
199. Arico M, Schrappe M, Hunger SP, et al: Clinical outcome of children with newly Antibodies and chimeric antigen receptors. Hematology Am Soc Hematol Educ Program
diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated 2013:131, 2013.
between 1995 and 2005. J Clin Oncol 28:4755, 2010. 224. DeAngelo DJ, Yu D, Johnson JL, et al: Nelarabine induces complete remissions in adults
200. Schultz KR, Bowman WP, Aledo A, et al: Improved early event free survival with ima- with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic
tinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children’s lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136, 2007.
Oncology Group Study. J Clin Oncol 27:5715, 2009. 225. Cohen MH, Johnson JR, Justice R, Pazdur R: FDA drug approval summary: Nelarabine
201. Schultz KR, Carroll A, Heerema NA, et al: Long-term follow-up of imatinib in pediatric (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist
Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology 13:709, 2008.
Group Study AALL0031. Leukemia 28:1467, 2014. 226. Dunsmore KP, Devidas M, Linda SB, et al: Pilot study of nelarabine in combination
202. Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lym- with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A
phoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet report from the Children’s Oncology Group. J Clin Oncol 30:2753, 2012.
359:1909, 2002. 227. Bhojwani D, Pui CH: Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol
203. Rowe JM: Interpreting data on transplant selection outcome in adult acute lymphoblas- 14:e205, 2013.
tic leukemia (ALL). Biol Blood Marrow Transplant 17:S76, 2011. 228. Mullighan GC, Phillips LA, Su X, et al: Genomic analysis of the clonal origins of
204. Pidala J, Djulbegovic B, Anasetti C, et al: Allogeneic hematopoietic cell transplantation relapsed acute lymphoblastic leukemia. Science 322:1377, 2008.
for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane 229. O’Brien S, Schiller G, Lister J, et al: High-dose vincristine sulphate liposome injection
Database Syst Rev (10):CD008818, 2011. for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute
205. Tucunduva L, Ruggeri A, Sanz G, et al: Risk factors for outcomes after unrelated cord lymphoblastic leukemia. J Clin Oncol 31:676, 2013.
blood transplantation for adults with acute lymphoblastic leukemia: A report on behalf 230. Huguet F, Leguay T, Raffoux E, et al: Clofarabine for the treatment of adult acute lym-
of Eurocord and the Acute Leukemia Working party of the European Group for Blood phoid leukemia: A review article by the GRAALL intergroup. Leuk Lymphoma 4:1, 2014.
and Marrow Transplantation. Bone Marrow Transplant 49:887, 2014. 231. Locatelli F, Schrappe M, Bernardo ME, Rutella S: How I treat relapsed childhood acute
206. Bachanova V, Verneris MR, DeFor T, et al: Prolonged survival in adults with acute lym- lymphoblastic leukemia. Blood 120:2807, 2012.
phoblastic leukemia after reduced-intensity conditioning with cord blood or sibling 232. Nguyen K, Devidas M, Cheng SC, et al: Factors influencing survival after relapse from
donor transplantation. Blood 113:2902, 2009. acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia 22:2142,
207. Mohty M, Labopin M, Volin L, et al: Reduced-intensity versus conventional myeloab- 2008.
lative conditioning allogeneic stem cell transplantation for patients with acute lym- 233. Bhatla T, Jones CL, Meyer JA, et al: The biology of relapsed acute lymphoblastic leuke-
phoblastic leukemia: A retrospective study from the European Group for Blood and mia: Opportunities for therapeutic interventions. J Pediatr Hematol Oncol 36:413, 2014.
Marrow Transplantation. Blood 116:4439, 2010. 234. Freyer DR, Devidas M, La M, et al: Postrelapse survival in childhood acute lymphoblas-
208. Wetzler M, Watson D, Stock W, et al: Autologous transplantation for Philadelphia tic leukemia is independent of initial treatment intensity: A report from the Children’s
chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to Oncology Group. Blood 117:3010, 2011.
allogeneic transplantation: Results of CALGB Study 10001 (Alliance). Haematologica 235. Paganin M, Zecca M, Fabbri G, et al: Minimal residual disease is an important predic-
99:111, 2014. tive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leuke-
209. Giebel S, Labopin M, Gorin NC, et al: Improving results of autologous stem cell mia. Leukemia 22:2193, 2008.
transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era 236. Doney K, Hagglund H, Leisenring W, et al: Predictive factors for outcome of allogeneic
of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood
the European Group for Blood and Marrow Transplantation. Eur J Cancer 50:411, Marrow Transplant 9:472, 2003.
2014. 237. Borgmann A, Schmid H, Hartmann R, et al: Autologous bone-marrow transplants
210. Ottmann OG, Wassmann B, Pfeifer H, et al: Imatinib compared with chemotherapy as compared with chemotherapy for children with acute lymphoblastic leukaemia in a
front-line treatment of elderly patients with Philadelphia chromosome-positive acute second remission: A matched-pair analysis. The Berlin-Frankfurt-Munster Study
lymphoblastic leukemia (Ph+ALL). Cancer 109:2068, 2007. Group. Lancet 346:873, 1995.
211. Vignetti M, Fazi P, Cimino G, et al: Imatinib plus steroids induces complete remissions 238. Smith AR, Baker KS, Defor TE, et al: Hematopoietic cell transplantation for children
and prolonged survival in elderly Philadelphia chromosome-positive acute lympho- with acute lymphoblastic leukemia in second complete remission: Similar outcomes
blastic leukemia patients without additional chemotherapy: Results of the GIMEMA in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA
LAL0201-B protocol. Blood 109:3676, 2007. matched sibling donors. Biol Blood Marrow Transplant 15:1086, 2009.
212. Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome-positive 239. Marks DI, Woo KA, Zhong X, et al: Unrelated umbilical cord blood transplant for adult
acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396, acute lymphoblastic leukemia in first and second complete remission: A comparison
2004. with allografts from adult unrelated donors. Haematologica 99:322, 2014.
213. Fielding AK, Rowe JM, Buck G, et al: UKALL XII/ECOG 2993: Addition of imatinib 240. Doney K, Gooley TA, Deeg HJ, et al: Allogeneic hematopoietic cell transplantation with
to a standard treatment regimen enhances long-term outcomes in Philadelphia positive full-intensity conditioning for adult acute lymphoblastic leukemia: Results from a sin-
acute lymphoblastic leukemia. Blood 123:843, 2014. gle center, 1998-2006. Biol Blood Marrow Transplant 17:1187, 2011.
214. Ravandi F, O’Brien S, Thomas D, et al: First report of phase 2 study of dasatinib 241. Borgmann A, von Stackelberg A, Hartmann R, et al: Unrelated donor stem cell trans-
with hyper-CVAD for the frontline treatment of patients with Philadelphia chromo- plantation compared with chemotherapy for children with acute lymphoblastic leuke-
some-positive (Ph+) acute lymphoblastic leukemia. Blood 116:2070, 2010. mia in a second remission: A matched-pair analysis. Blood 101:3835, 2003.
215. Zwaan CM, Rizzari C, Mechinaud F, et al: Dasatinib in children and adolescents with 242. Spyridonidis A, Labopin M, Schmid C, et al: Outcomes and prognostic factors of adults
relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell
study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.
31:2460, 2013. Leukemia 26:1211, 2012.
216. Biondi A, Schrappe M, De Lorenzo P, et al: Imatinib after induction for treatment of 243. Hagedorn N, Acquaviva C, Fronkova E, et al: Submicroscopic bone marrow involve-
children and adolescents with Philadelphia-chromosome-positive acute lymphoblas- ment in isolated extramedullary relapses in childhood acute lymphoblastic leukemia:
tic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol A more precise definition of “isolated” and its possible clinical implications, a collabo-
13:936, 2012. rative study of the Resistant Disease Committee of the international BFM study group.
217. Bachanova V, Marks DI, Zhang MJ, et al: Ph+ ALL patients in first complete remission Blood 110:4022, 2007.
have similar survival after reduced intensity and myeloablative allogeneic transplan- 244. Ribeiro RC, Rivera GK, Hudson M, et al: An intensive re-treatment protocol for
tation: Impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol
28:658, 2014. 13:333, 1995.

Kaushansky_chapter 91_p1505-1526.indd 1525 9/21/15 12:20 PM